Spectrum sues Cangene for breach of contract

Irvine, California-based Spectrum Pharmaceuticals is suing Cangene Biopharma in the U.S. District Court in Baltimore for allegedly breaching a 2008 contract to make Fusilev, an injectable cancer drug. Spectrum also accuses Cangene of failing to produce all of the drug it had ordered within the 60 days the contract requires, leaving Spectrum unable to fill orders for about 40,000 vials, according to the Baltimore Business Journal.

Spectrum added that it would be further damaged by Cangene's plans to temporarily close its Baltimore manufacturing plant for an undetermined period of time for maintenance and renovation, according to the lawsuit. It is seeking an unspecified amount of monetary damages and a court order forcing Cangene Biopharma to continue to manufacture Fusilev.

After the suit was filed Nov. 10, lawyers for both sides agreed that Cangene would keep its plant open through the close of business on Dec. 3. A motions hearing is scheduled for Nov. 23, according to the court's website.

- get more from the Baltimore Business Journal

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.